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Drugs that have been shown to cause drug-
induced immune hemolytic anemia or positive 
direct antiglobulin tests: some interesting 
findings since 2007
G. Garratty and P.A. Arndt
This review updates new findings in drug-induced immune-
hemolytic anemia (DIIHA) since the 2007 review in 
Immunohematology by these authors. Twelve additional drugs 
have been added to the three tables listing drugs associated 
with drug-dependent antibodies, drugs associated with 
drug-independent antibodies, and drugs associated with 
nonimmunologic protein adsorption. Other updated findings 
include (1) piperacillin is currently the most commonly 
encountered cause of DIIHA, (2) new data on blood group 
specificity of drug-dependent antibodies, (3) drug-dependent 
antibodies detected in healthy donors, (4) DIIHA associated with 
transplantation, and (5) DIIHA associated with chemotherapeutic 
drugs. Immunohematology 2014;30:66–79.
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Dr. Garratty has published five previous reviews 
on drug-induced immune hemolytic anemia (DIIHA) in 
Immunohematology; the last one in 2007 was coauthored by 
Pat Arndt.1–5 This issue is devoted to drug-induced immune 
cytopenias (red blood cells [RBCs], platelets, and white blood 
cells [WBCs]). If one reads the DIIHA reviews previously 
published in Immunohematology, you will get a view of how 
many drugs were found to be responsible over each 5-year 
period (1985–2007), which ones were the most common 
causes of DIIHA, and what concepts were most commonly 
suggested to explain various types of DIIHA. The reviews 
by Arndt6 and Leger et al.7 in this issue cover many of these 
areas in great detail and add new data that were not fully 
covered in the previous Immunohematology reviews. Some 
other recent reviews by Garratty can update you further.8–12 
For readers who do not have access to these publications,6–12 
we will summarize the most important information that has 
emerged in the last 10 years, with emphasis on the period 
since 2007.
Drugs Causing DIIHA
In our 2007 review, we included tables containing 125 
drugs that we believed had reasonable evidence of causing 
DIIHA.5 Indisputable evidence would require the following 
findings:
1. A well-defined hemolytic anemia (HA).
2. A temporal relationship to drug therapy and the start 
of the HA.
3. A positive direct antiglobulin test (DAT) after drug 
therapy (preferably with a negative DAT result 
preceding therapy).
4. Results of testing for drug antibodies (e.g., using 
drug-treated RBCs or testing serum in the presence 
of soluble drug7,8). These results must be accompanied 
by pertinent controls.7,8 Laboratory tests cannot 
prove that autoantibodies are drug-induced, but it 
is important to show that apparent autoantibodies 
are truly autoantibodies and not drug-dependent 
antibodies that are reacting without the in vitro 
addition of drug because enough drug is present in 
the patient’s plasma or serum.5–7,13
5. Patient responds hematologically after drug cessation. 
Unfortunately, this is not easy to define, as patients 
are often simultaneously given steroids.
Since 2007, we have added seven new drugs to Table 1 
(drug-dependent antibodies): hydrocortisone (2008), 
pemetrexed (2008), cimetidine (2010), etoricoxib (2013), 
iomeprol (2013), puerarin (2013), and vincristine (2013). 
Of these 115 drugs, five (carbromal, cefpirome, furosemide, 
methadone, and norfloxacin) may have caused positive 
DATs but no HA. Twenty-seven (23%) drugs were associated 
with drug antibodies reacting with drug-treated RBCs; 44 
(38%) drugs were associated with antibodies reacting in the 
presence of soluble drug; 41 (36%) drugs were associated 
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with antibodies detected by both methods. Fifty (43%) drugs 
were associated with in vitro reactions against untreated cells 
without any drug being added. These could be associated with 
drug-independent antibodies, but we believe that many may 
have been caused by drug or drug complexes being present 
in the patient’s plasma or serum (see footnote in Table 1). It 
will probably be no surprise that not all of the drugs listed in 
Table 1 satisfy 100% of our criteria for perfection. Hence, we 
can only say that there is reasonable evidence that these drugs 
were the cause of DIIHA.
We added four new drugs to Table 2 that appeared to cause 
autoimmune hemolytic anemia (drug-independent antibodies): 
rituximab (2003), alemtuzumab (2007), weidean (2009), and 
bendamustine (2013). All but one of the drugs in Table 2 
(chaparral) may have caused a DAT-positive autoimmune HA 
(AIHA). It should be noted that 16 of 21 drugs in this group 
were classified as needing more evidence to support that they 
belong in this group. One drug (cephaloridine) was added to 
the nonimmunologic protein adsorption group (Table 3); this 
was observed in 1967 but was unfortunately left off our 2007 
Table 3.
Classification of Drug Antibodies
There are two main types of drug antibodies: drug-
dependent antibodies and drug-independent antibodies.
Drug-dependent antibodies need the drug to be present for 
in vitro reactions; the drug can be bound to test RBCs or soluble 
drug can be added to patient’s plasma or serum (source of 
antibody) and allogeneic group O RBCs; after 37°C incubation, 
the tests are inspected for lysis, direct agglutination, and by 
the indirect antiglobulin test (IAT). Enzyme-treated RBCs 
should be used in addition to untreated RBCs.7 Test results 
are only valid when appropriate controls are used (see Leger et 
al.7 for complete details). Salama’s group does not advise using 
enzyme-treated RBCs169 because of problems with nonspecific 
reactions, but we believe these can usually be overcome with 
experience and pertinent controls.
Drug-independent antibodies react without any drug 
being added in vitro. The results are indistinguishable from 
RBC autoantibodies. It is thought that such drugs affect the 
immune system so that true autoantibodies and sometimes 
AIHA are produced. There are no special in vitro tests to define 
that a particular drug caused the AIHA. The diagnosis rests on 
the physician stopping the drug and finding that the anemia 
resolves, but the serology (e.g., DAT) can remain positive for 
some time longer.
Positive DATs and DIIHA Caused by Nonimmune 
Protein Adsorption
Drug-induced positive antiglobulin tests (e.g., DATs) and 
sometimes HA can occur with no drug antibodies involved, 
and yet RBCs are destroyed by macrophages in the spleen 
and liver. Thus, the drug interaction with the RBCs does not 
involve drug-induced antibodies, but the shortened life of the 
RBCs is by a cellular immune mechanism. The drugs that can 
be involved in this mechanism are listed in Table 3. These 
drugs can change the RBC membrane so that proteins (e.g., 
immunoglobulins, complement, albumin, etc.) attach to the 
RBCs, leading to positive antiglobulin tests. This may involve 
the patient’s RBCs in vivo (positive DAT), or may occur in 
vitro (positive IAT) when the patient’s serum or plasma is 
incubated with drug-coated RBCs (e.g., when testing for drug 
antibodies). This phenomenon was first observed with the 
first-generation cephalosporin, cephalothin, and was later 
found to occur with other cephalosporins (e.g., cefotetan). 
It was termed the “membrane modification mechanism” or 
“nonimmunological protein adsorption (NIPA).” It was thought 
for many years to be an interesting phenomenon that could 
interfere with interpretation of laboratory tests but had no 
clinical significance; then β-lactamase inhibitors, which cause 
NIPA, were shown to possibly cause DIIHA.162,167 Other drugs 
(see Table 3) can also cause NIPA and DIIHA (e.g., cisplatin 
and oxaliplatin). The involvement of NIPA is sometimes 
hard to define, as drug antibodies (e.g., anti-oxaliplatin) 
may also be involved.101 The nonimmunologically adsorbed 
immunoglobulin (Ig) G (and possibly C3) can react with 
receptors on macrophages, even though it is not an antibody 
to the drug or the RBCs. The most useful test to indicate that 
NIPA is occurring is to show that albumin is present on the 
RBCs by testing with anti-human albumin by the antiglobulin 
test.7 Such antisera have to be standardized carefully in-house, 
as no U.S. Food and Drug Administration–licensed reagent is 
available.
New Findings Since Our Last Review in 
Immunohematology (2007)
In the period covered by our 2007 review (2005–2007), 
the most common drugs to cause DIIHA in patients’ samples 
submitted to our laboratory were cefotetan, ceftriaxone, 
and piperacillin, in that order. For the period 2008–2013, 
piperacillin, rose to number 1, followed by cefotetan and 
ceftriaxone (Table 4). We are starting to see a small increase in 
DIIHA caused by drugs in the platinum family.
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Aceclofenac 14 NSAID Single (1997)
Acetaminophen (Paracetamol) 15,16 NSAID Multiple (<10)
Acyclovir 17 Antiviral Single (2003)
Aminopyrine 18 NSAID Single (1961)
Amoxicillin 19 Antimicrobial Multiple (<5)
Amphotericin B 20 Antimicrobial Multiple (<5) †
Ampicillin 21 Antimicrobial Multiple (<10)
Antazoline 22 Antihistamine Multiple (<5)
Aspirin 23 Analgesic, antipyretic,  
anti-inflammatory
Single (1984)
Azapropazone (Apazone) 24 Anti-inflammatory, 
analgesic
Multiple (<5)
Buthiazide (Butizide) 25 Diuretic, antihypertensive Single (1984) †
Carbimazole 26 Antithyroid Multiple (<5)
Carboplatin‡ 27 Antineoplastic Multiple (<10)
Carbromal 28 Sedative, hypnotic Single (1970)
Catechin [(+)-Cyanidanol-3] 
(Cianidanol)
29 Antidiarrheal Multiple (≥10) †
Cefamandole 30 Antimicrobial Single (1985)
Cefazolin 31 Antimicrobial Multiple (<10)
Cefixime 32 Antimicrobial Single (2000)
Cefotaxime‡ 33 Antimicrobial Multiple (<5) **
Cefotetan‡ 34–38 Antimicrobial Multiple (≥10) ¶
Cefoxitin‡ 39 Antimicrobial Multiple (<10)
Cefpirome 40 Antibacterial Single (2005)
Ceftazidime 41 Antimicrobial Multiple (<10)
Ceftizoxime 42 Antimicrobial Multiple (<5) **
Ceftriaxone‡ 43,44 Antimicrobial Multiple (≥10) † **
Cefuroxime 45 Antibacterial Multiple (<5)
Cephalexin 46 Antimicrobial Multiple (5) ¶
Cephalothin‡ 47–49 Antimicrobial Multiple (≥10) ¶
Chloramphenicol 50 Antibacterial Multiple (<5)
Chlorinated hydrocarbons 51 Insecticides Multiple (<10)
Chlorpromazine 52 Antiemetic, antipsychotic Multiple (<10)
Chlorpropamide‡ 53,54 Antidiabetic Multiple (<10) **
Cimetidine‡ 55 Antiulcerative Single (2010)
Ciprofloxacin 56 Antibacterial Multiple (<10)
Cisplatin (Cisdiamino-
dichloroplatinum)
57,58 Antineoplastic Multiple (<10) ¶
Cloxacillin 59 Antibacterial Single (1980)
Cyclofenil 60 Gonad-stimulating 
principle
Multiple (<5)
Table 1. Drugs associated with cases of IHA or positive DAT, or both, in which drug-dependent antibodies were detected*
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Cyclosporin (Cyclosporine) 61 Immunosuppressant Multiple (<5)
Dexchlorpheniramine maleate 
(Chlorpheniramine)
62 Antihistaminic Single (1981)
Diclofenac‡ 63–66 NSAID Multiple (≥10) † **
Diethylstilbestrol (Stilboestrol) 67 Estrogen Multiple (<5)
Dipyrone 68 NSAID Multiple (<5)
Erythromycin‡ 69 Antimicrobial Multiple (<5)
Etodolac 70 NSAID Single (2000) †
Etoricoxib 71 NSAID Single (2013) † **
Ethambutol 17 Antibacterial Single (2003)
Fenoprofen 72 NSAID Single (1988) **
Fluconazole 17 Antifungal Single (2003)
Fluorescein 73 Injectable dye Single (1993) **
Fluorouracil 74 Antineoplastic Multiple (<10) †
Furosemide 40 Diuretic Multiple (<5)
Glafenine (Glaphenine) 75,76 Analgesic Multiple (<5) †
Hydralazine 77 Antihypertensive Single (1977)
Hydrochlorothiazide‡ 78 Diuretic Multiple (<10) **
9-Hydroxy-methyl-ellipticinium 
(elliptinium acetate)
79 Antineoplastic Multiple (<5)
Hydrocortisone 80 Glucocorticoid Single (2008)
Ibuprofen 81 NSAID Multiple (<5)
Imatinib mesylate 82 Antineoplastic Multiple (<5)
Insulin 83 Antidiabetic Multiple (<5)
Iomeprol 84 Radiopaque medium Single (2013) **
Isoniazid 85 Antimicrobial Multiple (<10)
Latamoxef (Moxalactam) 75 Antimicrobial Single (1985)
Levofloxacin (Ofloxacin) 86 Antibacterial Multiple (<5)
Mefloquine‡ 87 Antimicrobial Multiple (<5) **
Melphalan 88 Antineoplastic Single (1967)
6-Mercaptopurine 89 Antineoplastic Single (2000)
Methadone 90 Analgesic Multiple (<5)
Methotrexate 91 Antineoplastic, 
antirheumatic
Multiple (<5)
Metrizoic acid 92 Radiopaque medium Single (1991)
Minocycline 93 Antibacterial Single (1994)
Nabumetone 94 Anti-inflammatory, 
analgesic
Single (2003) †
Nafcillin‡ 95 Antimicrobial Multiple (<10)
Naproxen 96 Anti-inflammatory, 
analgesic, antipyretic
Multiple (<5)
Nitrofurantoin 97 Antibacterial Single (1981)
Table 1. Drugs associated with cases of IHA or positive DAT, or both, in which drug-dependent antibodies were detected* (continued)
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Nomifensine§ 98 Antidepressant Multiple (≥10) † **
Norfloxacin 99 Antimicrobial Single (1999)
Oxaliplatin‡ 100, 101 Antineoplastic Multiple (≥10) ¶ **
p-Aminosalicylic acid (PAS) (para-
aminosalicylsäure)
102 Antimicrobial Multiple (<10)
Pemetrexed 103 Antineoplastic Multiple (<5)
Penicillin G‡ 104, 105 Antimicrobial Multiple (≥10)
Phenacetin‡ (Acetophenetidin) 106 NSAID Multiple (≥10)
Phenytoin (Fenitoine) 17 Anticonvulsant, 
antiarrhythmic
Single (2003)
Piperacillin‡ 107 Antimicrobial Multiple (≥10) **
Probenecid‡ 108 Uricosuric Multiple (<5) **
Propyphenazone 109 NSAID Single (1998)
Puerarin 110 Chinese herb Multiple (<5)
Pyrazinamide 17 Antibacterial Single (2003) 
Pyrimethamine (Pirimetamine) 17 Antimicrobial Multiple (<5)
Quinidine 111 Antiarrhythmic, 
Antimicrobial
Multiple (≥10) **
Quinine 106 Antimicrobial Multiple (<10)
Ranitidine 112 Antiulcerative Multiple (<5)
Rifabutin 17 Antibacterial Single (2003)
Rifampin‡ (Rifampicin) 113–115 Antibacterial Multiple (≥10) **
Stibophen 116 Antimicrobial Multiple (<5)
Streptokinase 117 Thrombolytic Single (1989)
Streptomycin 118–120 Antimicrobial Multiple (<10)
Sulfasalazine 121 Anti-inflammatory Multiple (<5)
Sulfisoxazole 17 Antibacterial Single (2003)
Sulindac 122 Anti-inflammatory Multiple (<10) **
Suprofen 123 NSAID Single (1989) **
Tartrazine 124 Colorant Single (1979)
Teicoplanin 125 Antimicrobial Multiple (<5)
Temafloxacin§ 126 Antimicrobial Multiple (<5)
Teniposide 127 Antineoplastic Single (1982)
Tetracycline 128 Antimicrobial Multiple (<10)
Thiopental sodium 129 Anesthetic Single (1985)
Ticarcillin‡ 130 Antimicrobial Multiple (<5)
Tolbutamide 131 Antidiabetic Multiple (<5)
Tolmetin‡ 132 NSAID Multiple (≥10) **
Triamterene 133 Diuretic Multiple (<5)
Trimellitic anhydride 134 Used in prep of resins, 
dyes, adhesives, etc.
Multiple (<5)
Table 1. Drugs associated with cases of IHA or positive DAT, or both, in which drug-dependent antibodies were detected* (continued)
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135 Antibacterial Multiple (<5)
Vancomycin 17 Antibacterial Single (2003)
Vincristine 136 Antineoplastic Single (2013)
Zomepirac 137 NSAID Single (1983)
IHA = immune hemolytic anemia; DAT = direct antiglobulin test; HA = hemolytic anemia; RBCs = red blood cells; NSAID = nonsteroidal anti-inflammatory 
drug.
*  When a drug antibody is indicated to be reactive by two methods, e.g., vs. drug-treated RBCs and when serum + drug + RBCs are mixed together,  not all 
cases necessarily had drug antibodies reactive by both methods. Using ampicillin, for example, four reported antibodies reacted with drug-treated RBCs and 
were either nonreactive (n = 1) or not tested (n = 3) by the serum + drug + RBCs method, and two antibodies reacted when serum + drug + RBCs were 
tested but were nonreactive with drug-treated RBCs.
† One or more samples only positive or strongest reactions seen with ex vivo (urine or serum) or metabolite.
‡ Cases of DIIHA or positive DAT caused by these drugs have been identified in Dr. Garratty’s laboratory.
§ No longer manufactured.
¶ Associated with nonimmunologic protein adsorption (NIPA).
**One or more samples positive, possibly owing to the presence of circulating drug or drug-antibody immune complexes.
Table 1. Drugs associated with cases of IHA or positive DAT, or both, in which drug-dependent antibodies were detected* (continued)
Table 2. Drugs associated with cases of IHA or positive DAT or both in which only drug-independent antibodies (autoantibodies) were 
detected
Drug (alternative name) Reference Therapeutic category
Number of references  
(single [year] vs. multiple 




Alemtuzumab 138 Antineoplastic; immunosuppressant Multiple (<5)
Bendamustine 139 Antineoplastic Multiple (<5)
Captopril 140 Antihypertensive Multiple (<5)
Chaparral 141 Herbal Single (1980)
Cimetidine 142 Antiulcerative Multiple (<10)
Cladribine (2-chloro-deoxyadenosine) 143 Antineoplastic Multiple (<10)
Fenfluramine 144 Anorexic Single (1973)
Fludarabine* 145,146 Antineoplastic Multiple (≥10)
Interferon 147 Antineoplastic, antiviral Multiple (≥10)
Interleukin-2 148 Antineoplastic Multiple (<5)
Ketoconazole 149 Antifungal Single (1987)
Lenalidomide 150 Immunomodulatory Single (2006)
Levodopa (L-dopa) 151 Antiparkinsonian Multiple (≥10)
Mefenamic acid 152 NSAID Multiple (≥10)
Mesantoin (Mephenytoin) 153 Anticonvulsant Single (1953)
Methyldopa* 154 Antihypertensive Multiple (≥10)
Nalidixic acid 155 Antibacterial Multiple (<10)
Procainamide* 156,157 Antiarrhythmic Multiple (<10)
Rituximab 158 Antineoplastic Single (2003)
Tacrolimus 159 Immunosuppressant Multiple (<10)
Weidean 160 Chinese herbs Single (2009)
IHA = immune hemolytic anemia; DAT = direct antiglobulin test; HA = hemolytic anemia; NSAID = nonsteroidal anti-inflammatory drug.
*Cases of drug-induced immune hemolytic anemia or positive DAT caused by these drugs have been identified in Dr. Garratty’s laboratory.
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Drug Antibodies Showing Blood Group Specificity
I (G.G.) have been interested in this area for more than 
30 years. The first report (in 1977) concerned a streptomycin 
antibody having Rh specificity.118 In 1981, Duran-Suarez et 
al.97 described antibodies to three drugs with I specificity. In 
1984, we described a chlorpropamide-induced autoanti-Jka.54 
In 1983 and 1985, Habibi et al.129,170 and, in 1986, Salama 
and Mueller-Eckhardt171 added more drugs showing this 
phenomenon. The list has grown quite long (see Table 1 of 
Arndt6), but this is still not a common finding. There are many 
piperacillin antibodies showing blood group antigen specificity 
that have been described since 1984.107,172 Most of these were 
Rh specificities (especially anti-e or “relative” anti-e specificity). 
Of 37 piperacillin antibodies we were sent to investigate, the 
referring laboratories detected 8 anti-e, 1 anti-e–like antibody, 
and 1 possible anti-f when testing serum without piperacillin 
added in vitro (in vivo circulating piperacillin was most likely 
present). Twenty-seven of these were tested with R1R1 and 
R2R2 RBCs in the presence of in vitro added piperacillin; 16 of 
27 (59%) were nonreactive (7) or weaker (9) with R2R2 RBCs 
(e.g., e or relative e specificity), and 2 (8%) were weaker with 
R1R1 RBCs (relative c specificity).172
In 2013, we reported results of tests from our own 
laboratory during the last 30 years on 53 antibodies to 13 
different drugs.172 We found no blood group specificity in 
single examples of antibodies to acetaminophen, phenacetin, 
probenecid, quinidine, teniposide, cefotaxime, cimetidine, or 
diclofenac, four examples of anti-ceftriaxone, or ten examples of 
anti-cefotetan. We found some blood group antigen specificities 
associated with sulfamethoxazole (MNS and Lutheran) and 
piperacillin (Rh and Lutheran). Some specificities only became 
apparent when the antibodies were diluted.
Drug Antibodies Detected in Healthy Blood Donors
We have known for many years that healthy humans can 
have drug antibodies in their plasma or serum. Low-titer, often 
IgM, penicillin antibodies were detected in blood donors (5%) 
or patients with DIIHA (6%). This finding did not confuse the 
serologic diagnosis because patients with penicillin DIIHA 
had very high titer (>1000), usually IgG, penicillin antibodies. 
About 30 to 40 percent of blood donors were found to have 
antibodies to cephalothin and ticarcillin. Problems were 
encountered when it was noticed that 80 percent of donors 
and patients with no DIIHA had cefotetan antibodies; luckily, 
patients with DIIHA had very high titers of cefotetan antibodies 
compared with patients with no HA. The most interesting 
results in this area involved piperacillin. In 2008, we reported 
G. Garratty and P.A. Arndt
Table 3. Drugs associated with the detection of nonimmunologic protein adsorption onto RBCs
Drug (alternative name) Reference Therapeutic category
Number of references 
(single [year] vs. multiple  






Cefotetan* 35,36 Antimicrobial Multiple (≥10)
Cephaloridine 48 Antimicrobial Multiple (<5)
Cephalothin* 47,48 Antimicrobial Multiple (≥10)
Cisplatin 58 Antineoplastic Multiple (<10)
Clavulanate potassium* (Clavulanic acid) 161,162 β-Lactamase inhibitor Multiple (<5)
Diglycoaldehyde (INOX) 163,164 Antineoplastic Multiple (<5)
Oxaliplatin* 101 Antineoplastic Multiple (≥10)
Sulbactam* 161,165 β-Lactamase inhibitor Multiple (<5)
Suramin 166 Antihelminthic, antiprotozoal Single (1988)
Tazobactam* 167,168 β-Lactamase inhibitor Multiple (<5)
RBCs = red blood cells; HA = hemolytic anemia; DAT = direct antiglobulin test; IHA = immune hemolytic anemia.
*Cases of drug-induced immune hemolytic anemia or positive DAT caused by these drugs have been identified in Dr. Garratty’s laboratory.
Table 4. Drug antibodies detected by the Research Lab at the 
American Red Cross in Pomona, CA, from 1978 to 2013
Years Ceftriaxone Cefotetan Piperacillin
Platinum-
based drugs Other drugs
1978–83 0 0 0 0 7
1984–89 2 0 0 0 4
1990–95 2 20 0 0 7
1996–2001 6 45 2 0 6
2002–07 7 15 6 3 7
2008–13 14 13 30 5 6
Total 31 93 38 8 37
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that 91 percent of donors’ sera and 49 percent of random 
patients’ sera, contained piperacillin antibodies reactive 
against piperacillin-coated RBCs.173 Luckily, we determined 
that antibodies to piperacillin (unlike antibodies to other 
penicillins) react well by adding soluble drug solution to the 
patients’ sera, and this reactivity correlated with the DIIHA. 
We no longer use piperacillin-coated RBCs in screening tests. 
A few other drug antibodies have been detected in healthy and 
sick individuals with no DIIHA (oxaliplatin,174 cisplatin,174 and 
meropenem175).
It is not known why some of the preceding drug antibodies 
are found in healthy donors or why they sometimes appear 
more commonly in healthy donors than in random patients. For 
instance, 91 percent of donors and only 49 percent of random 
patients have piperacillin antibodies; 16 percent of donors and 
only 4 percent of patients have oxaliplatin antibodies.
It has been suggested that environmental factors may 
be responsible for the production of antibodies. For instance, 
automobile catalytic convertors release platinum into the 
atmosphere and may explain the production of antibodies 
to drugs that belong to the platinum family (oxaliplatin, 
carboplatin, and cisplatin). Another major concept to explain 
the production of antibodies to antibiotics in individuals with no 
DIIHA is that, in the United States, antibiotics are routinely fed 
to cattle and chickens, so we are continually exposed to drugs 
such as the cephalosporins and penicillins. Many countries in 
Europe have banned this practice mainly to prevent problems 
with treatment resistance of many organisms.
DIIHA Associated With Transplantation
Many of the drugs used for transplantation are designed 
to affect the immune system, so we should not be surprised to 
see true AIHA develop sometimes. Trying to prove the cause 
of HA or production of RBC autoantibodies (e.g., positive DAT 
or IAT) is a difficult task, but DIIHA has to be considered. 
Examples of drugs said to cause DIIHA after transplantation 
are cyclosporine, tacrolimus, and the combination of 
alemtuzumab, mycophenolate, and daclizumab. It is almost 
impossible to prove that the HA is caused by one of these drugs, 
so publications (e.g., Elimelakh et al.138) often hypothesize 
that the combination of such drugs has caused the immune 
aberrations. There are often no demonstrable drug-dependent 
antibodies but often the presence of drug-independent 
antibodies (autoantibodies). Some interesting points are 
(1) some of the AIHAs have not been warm AIHA but are 
associated with cold agglutinins, (2) there are interesting 
associations with posttransplant lymphoproliferative disorder 
(PTLD),159 and (3) the hemolytic anemia can develop long after 
the transplant and long after therapy with the suspected drug 
(e.g., up to 2 years).
DiGiuseppe et al.159 reported on a child who had a liver 
transplant at 1 year old; he was successfully maintained on 
cyclosporine for 4 years and then switched to tacrolimus, 
which was increased from 2 mg to 8 mg twice daily. The 
patient developed AIHA; his hemoglobin fell to 3.5 g/dL 
after transfusion of one unit of RBCs, and he died. Post-
mortem examination revealed a clinically unsuspected PTLD. 
Elimelakh et al.138 reported on cases of red cell aplasia (RCA) 
and AIHA after immunosuppression with alemtuzumab (anti-
CD52), mycophenolate mofetil (MMF), and daclizumab (anti-
Tac/CD25) in pancreas transplant patients. Data from a 2-year 
period were reported for 357 pancreas transplants. AIHA was 
detected in 16 patients (7 of these also had RCA; 3 had RCA 
only). All were DAT+ (all but one had RBC-bound IgG + C3). 
When MMF was discontinued in the RCA/AIHA group, seven 
patients recovered from RCA, but only three also recovered 
from the HA. In the AIHA-alone group (nine patients), MMF 
was discontinued in two patients with no effect on the HA. 
Other patients in this group were treated with steroids, 
rituximab, intravenous IgG, splenectomy, or plasma exchange, 
with remission seen in only two of the nine patients. The 
authors suggested that a combination of the drugs may have 
been involved in the AIHA. It is interesting that the RCA, 
which is thought to be caused by autoantibody to early RBC 
precursors, appeared to be caused by MMF.
Drug-Induced AIHA Associated With 
Chemotherapeutic Drugs
Although several chemotherapeutics have been suggested 
to cause DIIHA, similar problems to those of the transplant 
associations make the diagnosis difficult. Often several drugs 
are involved and no drug-dependent antibodies are detectable; 
the antibodies are usually drug-independent and the patient 
appears to have developed a true AIHA. The best examples 
of such drugs are the purine analogs (e.g., fludarabine and 
cladribine) used to treat patients with chronic lymphocytic 
leukemia (CLL). Hemolytic anemia after fludarabine therapy 
occurred in 14 of 66 (22%),176 9 of 52 (17%),177 5 of 36 (14%),178 
and 5 of 104 (5%)146 patients. The analyses of patients with 
CLL are more complex, with many more confounding factors 
than the data accumulated in the 1970s on the prototype drug 
(methyldopa), which inclues RBC autoantibodies and AIHA in 
patients taking the drug for hypertension. Patients with CLL 
are a very different group of patients, as CLL is known to be 
associated with positive DATs and AIHA without any drug 
involvement. Nevertheless, there are reports of exacerbation 
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of AIHA that was present before fludarabine therapy. There 
are fewer reports of AIHA caused by fludarabine in de novo 
CLL patients receiving fludarabine for the first time compared 
with patients who have had multiple courses of alkylating 
agents among whom the prevalence is about 20 percent. There 
are reports of catastrophic hemolysis (some fatalities) after 
fludarabine therapy.
In 2008, an interesting study of 777 patients with CLL 
randomly assigned to receive chlorambucil (C) or fludarabine 
(F) alone or with cyclophosphamide (FCy) was published.179 
Fourteen percent of these patients had a pretreatment positive 
DAT. Only 28 percent of patients with positive DATs had an 
associated HA. Of 249 patients, those treated with F were 
most likely to become DAT-positive. Patients treated with F 
or C were twice as likely as those treated with FCy to have 
AIHA. The authors concluded that a positive DAT was a good 
prognostic indicator and that FCy combination therapy may 
protect against AIHA. There is an excellent review on AIHA in 
patients with CLL by Hamblin.180
In one publication, 300 patients with CLL taking 
fludarabine, cyclophosphamide, and rituximab were followed.181 
Nineteen (6.5%) developed HA. The authors considered these 
to be AIHA even though 82 percent of the DATs were negative. 
Such cases of DAT-negative AIHA have been reported in other 
publications on fludarabine-induced HA.
Recently, there has been an interesting association 
between fludarabine and bendamustine, a chemotherapeutic 
drug that is also used for CLL and lymphoma. Several cases of 
bendamustine-associated AIHA (involving drug-independent 
autoantibodies) have been described. Goldschmidt et al.139 
reported on five cases of AIHA in 31 CLL patients treated 
with bendamustine; none of the non-CLL patients developed 
AIHA; and two of five cases were DAT-negative. All five 
cases had received fludarabine previously. One single case of 
bendamustine-associated AIHA was DAT-negative and had 
received no previous fludarabine.182 Although fludarabine is 
a purine nucleoside and bendamustine is an alkylating agent, 
it contains a purine-like benzimidazole ring. This might 
explain why the bendamustine appeared to give a more severe 
“secondary” response in patients who had sometimes had a 
less severe HA caused by fludarabine.
Closing
As new therapeutic drugs appear, we will need to be aware 
of their potential for inducing drug-dependent antibodies, 
drug-independent antibodies, or NIPA. The diagnosis is not 
always easy, and as stated in previous summaries,2,4 when 
studying DIIHA, we typically end up with more questions 
than answers!
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